P/B
1,2
Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
$674.3M
Market Cap • 9/28/2026
2018
(8 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
7,9
EPS
—
Market Cap
Market Cap
674,3M
EV
492,5M
EV/Revenue
0
EV/EBITDA
-7,6
EV/EBIT
-7,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,1%
Total Yield
-0,1%
Payout
0%
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
283,8%
Capex/OCF
-0,7%
SBC/OCF
—
% PPE
0,8%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
14,5%
CAGR Net Income 5Y
5,3%
CAGR EPS 5Y
-44,1%
CAGR OCF 5Y
17,8%
Leverage
N.D./EBITDA
2,8
Debt/Equity
0%
Current Ratio
31,5
Quick Ratio
30,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!